What is the dosing and frequency of metronidazole (Metro)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Metronidazole Dosing and Frequency

For trichomoniasis, the recommended regimen is metronidazole 2 g orally in a single dose, with an alternative regimen of metronidazole 500 mg twice daily for 7 days. 1

Standard Dosing Regimens by Indication

Trichomoniasis

  • First-line treatment: Metronidazole 2 g orally in a single dose 1
  • Alternative regimen: Metronidazole 500 mg twice daily for 7 days 1
  • FDA has approved Flagyl 375 mg twice daily for 7 days for trichomoniasis based on pharmacokinetic equivalency with metronidazole 250 mg three times daily for 7 days 1

Bacterial Vaginosis (BV)

  • Metronidazole 500 mg twice daily for 7 days 1
  • Alternative: Metronidazole 2 g orally in a single dose 1

Intraabdominal Infections

  • 500 mg every 8 hours (typically for 7-10 days) 2
  • Duration may be limited to 4-7 days if adequate source control is achieved 2

Pharmacokinetic Considerations

  • Metronidazole has excellent bioavailability (>90%) when administered orally 3
  • The elimination half-life is approximately 8 hours in healthy adults 4, 3
  • Less than 20% of metronidazole is bound to plasma proteins 4, 3
  • The drug is extensively metabolized in the liver with 5 oxidative metabolites 4, 5
  • Approximately 60-80% of the dose is excreted in urine, with 6-15% in feces 4
  • Only about 20% of the drug is excreted unchanged in urine 4, 3

Special Populations

Pregnancy

  • Metronidazole is contraindicated in the first trimester of pregnancy 1
  • After the first trimester, 2 g of metronidazole in a single dose can be used 1
  • For pregnant women with symptomatic BV, metronidazole 250 mg orally three times daily for 7 days is recommended 1

Renal Dysfunction

  • No dosage adjustment is necessary in patients with renal dysfunction 3
  • While renal dysfunction reduces elimination of metronidazole metabolites, no toxicity has been documented 3

Hepatic Dysfunction

  • Plasma clearance of metronidazole is decreased in patients with decreased liver function 4
  • Dosage reduction is recommended in liver disease 3

Treatment Failures and Resistant Infections

  • If treatment failure occurs with either standard regimen for trichomoniasis, the patient should be re-treated with metronidazole 500 mg twice daily for 7 days 1
  • For repeated treatment failures, a single 2 g dose of metronidazole once daily for 3-5 days is recommended 1
  • Resistance to metronidazole is rare but has been documented 5, 3

Common Pitfalls and Caveats

  • Metronidazole gel is approved for BV but is not recommended for trichomoniasis as it does not achieve therapeutic levels in the urethra or perivaginal glands 1
  • Prolonged or repeated courses of metronidazole should be avoided due to the risk of cumulative and potentially irreversible neurotoxicity 2
  • Patients should be instructed to avoid alcohol while taking metronidazole due to potential disulfiram-like reaction 5
  • Drug interactions have been reported with alcohol, warfarin, and phenytoin 5
  • Clinical studies have demonstrated that twice-daily dosing can be as effective as three-times-daily dosing in certain clinical scenarios, supporting the pharmacokinetic data 6

By following these evidence-based dosing recommendations, clinicians can optimize treatment outcomes while minimizing the risk of adverse effects and antimicrobial resistance.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Timing of Oral Metronidazole After IV Administration for Colon Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Metronidazole].

Annales de dermatologie et de venereologie, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.